Mounjaro®
Starting from £179.99/mo
Start journey Learn moreYes, most people do regain some weight after stopping weight loss injections. This is not a personal failure — it reflects how these medicines work. GLP-1 and dual-agonist treatments reduce appetite and slow gastric emptying while you take them; once the drug clears your system, those effects wear off and hunger returns. The question is not really whether some regain happens, but how much, how fast, and what can be done about it. These are prescription-only medicines, and decisions about stopping, continuing or switching are ones to make with a prescriber who knows your full history — not alone.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
A question our prescribers hear most weeks goes something like this: "If I lose the weight I need to lose, can I just stop and stay there?" It is a completely understandable hope, and a reasonable one to examine carefully. The honest answer is that for most people, stopping the injection does not lock in the result.
The STEP 1 extension trial, published in the New England Journal of Medicine, followed participants who had completed 68 weeks of semaglutide treatment and then stopped. Within a year of stopping, they had regained around two-thirds of the weight they had lost. Appetite returned, energy intake increased, and the biological signals that had been quietened by the medicine came back. This is not unusual, it mirrors what happens after stopping most effective weight-loss treatments.
The reason is rooted in how obesity works as a condition. It involves persistent hormonal and neurological drivers that do not simply reset after a period of treatment. The NHS obesity overview describes obesity as a chronic condition with complex underlying causes, which is precisely why effective medicines for it tend to be long-term ones. Believing that a course of injections permanently rewires appetite is the biggest misconception to correct before making any decision about stopping.
GLP-1 and dual-agonist medicines work by mimicking hormones that signal fullness and regulate how quickly food leaves the stomach. While the medicine is active, appetite is meaningfully suppressed and many people find they are satisfied with less food without needing to rely on willpower. Stop the injection, and within days to weeks those effects fade as the drug leaves the system.
For tirzepatide (the dual GIP and GLP-1 receptor agonist licensed in the UK as Mounjaro) the half-life means drug levels fall steadily over roughly five days after the last dose, with clinically meaningful effects largely gone within a few weeks. For semaglutide (Wegovy), the clearance is similar. There is no sudden dramatic reversal; hunger tends to creep back rather than surge. But creep back it does.
How quickly weight returns varies. People who have built consistent dietary habits and increased their physical activity during treatment tend to regain more slowly. Those who relied heavily on the medicine's appetite suppression without building those parallel habits often regain faster. That is not a moral judgement, it reflects the practical reality that lifestyle changes made alongside treatment act as a partial buffer once treatment stops. Our overview of weight loss injections covers how these medicines are designed to work alongside, not instead of, dietary and activity changes.
Not entirely. Some people do maintain a portion of their weight loss, particularly those who used the treatment period to make lasting changes to eating patterns and activity levels. If you want a fuller picture of what the evidence shows, our page on whether you put weight back on after weight loss injections walks through the clinical data in detail. But the clinical evidence is clear that significant, sustained maintenance of the full amount lost is uncommon without continuing treatment of some kind.
This is one reason NICE's recommendation for tirzepatide, detailed in technology appraisal TA1026, includes a review at six months to assess whether treatment is delivering enough benefit to continue, the framework presumes ongoing use rather than a fixed course. The NICE recommendation for semaglutide similarly envisages treatment within specialist services rather than a short-term course followed by stopping.
If you are considering stopping because of side effects, cost, or a feeling that you have reached your goal, those are all worth discussing before making the call. There may be options worth exploring: a lower maintenance dose, a pause rather than a permanent stop, or a structured plan for what happens next. The detail of how to stop weight loss injections safely matters more than most people realise.
It is also worth being honest about what "stopping" means in practice. Some people stop intentionally; others stop because supply runs out, because cost becomes difficult, or because they feel well enough that treatment feels unnecessary. Each situation is different. What is consistent across them is that regain tends to follow, and that a planned stop (with prescriber input) gives you a better chance of holding onto more of what you gained.
The most useful thing you can do before stopping is to speak to a prescriber, not after regain has already started. A prescriber can review your current dose, your goals, and your lifestyle changes so far, and help you think through the options. These options might include continuing at the lowest effective dose, transitioning to a different approach, or stopping with a clear plan for monitoring and support.
If you are thinking about your longer-term weight loss journey as a whole, treatment decisions sit within that broader picture rather than standing alone. Looking at weight loss injections before and after results from real patients can help ground your expectations in what is realistically achievable, both during treatment and once it stops. The goal of treatment is not just a number on the scales during the active phase, it is a sustainable position afterwards.
For those weighing up whether to continue or stop, the question of whether stopping is the right decision involves more clinical nuance than a simple yes or no. At nume, every repeat order is reviewed by a GPhC-registered Independent Prescriber before it is approved, the same clinical care applies whether you are asking about continuing or about stopping. If you would like that conversation, check your eligibility and start a free consultation, and if you are specifically using or considering tirzepatide, our guide to the Oz weight loss injection covers what to expect at each stage of treatment.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.